Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) will report 2025 full-year financial results and provide a business update on Tuesday, March 17, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. An archived replay will be available on the company website under Events & Presentations.

Market Context

This announcement sets the timetable for Longeveron’s full-year 2025 financial results and a busines...

Analysis

This announcement sets the timetable for Longeveron’s full-year 2025 financial results and a business update on March 17, 2026, with a conference call at 4:30 p.m. ET. It signals upcoming detail on performance and strategy but provides no figures yet. Investors may focus on revenue trends, cash position, and development milestones once disclosed, using the call and archived webcast to evaluate how the update fits into the company’s broader trajectory.

Key Figures

Results period: 2025 full year Earnings date: March 17, 2026 Conference time: 4:30 p.m. ET +2 more

5 metrics

Results period 2025 full year Financial results to be reported

Earnings date March 17, 2026 Scheduled full-year 2025 release after U.S. market close

Conference time 4:30 p.m. ET Conference call and webcast start time

Conference call number 1.877.407.0789 Dial-in for earnings conference call

Conference ID 13758462 Access code for conference call

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

Conference Call and Webcast Details:

Conference Call Number:	1.877.407.0789
Conference ID:	13758462
Call meTM Feature:	Click Here
Webcast:	Click Here

An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B^®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), Pediatric Dilated Cardiomyopathy (PDCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

FAQ

When will Longeveron (LGVN) release its 2025 full-year results and hold the conference call?

Longeveron will release 2025 full-year results on Tuesday, March 17, 2026 after market close. According to Longeveron, the company will host a conference call and webcast the same day at 4:30 p.m. ET to review results and provide a business update.

How can investors join the Longeveron (LGVN) conference call and webcast on March 17, 2026?

Investors can join the conference call at 1.877.407.0789 using Conference ID 13758462. According to Longeveron, a live webcast link will also be provided on the company website for online access during the 4:30 p.m. ET call.

Will a replay of the Longeveron (LGVN) March 17, 2026 webcast be available for later access?

Yes, an archived replay will be available after the call on the company website. According to Longeveron, the replay will be posted in the Events & Presentations section following the conference for on-demand viewing.

What time is the Longeveron (LGVN) conference call on March 17, 2026 and which time zone is used?

The conference call is scheduled for 4:30 p.m. ET on March 17, 2026. According to Longeveron, times are stated in Eastern Time, with the call occurring after U.S. financial markets close that day.

What topics will Longeveron (LGVN) cover during the March 17, 2026 business update call?

The company will report 2025 full-year financial results and provide a business update during the call. According to Longeveron, the presentation will cover financial results and updates on the company’s clinical-stage programs and corporate progress.

Is there a Conference ID or callback feature for the Longeveron (LGVN) March 17, 2026 call?

Yes, the Conference ID is 13758462 and a Call Me feature is available for dial-out. According to Longeveron, callers may use the provided Call Me feature or the dial-in number 1.877.407.0789 to join the live call.